Last year marked a decade since the first checkpoint inhibitor, a monoclonal antibody (mAb) against CTLA4, was approved by the FDA to treat melanoma. This approval revolutionized cancer treatment and paved the way for clinical advances with immune checkpoint inhibitors and other immuno-oncology (IO) therapies. To date, the FDA has approved seven immune checkpoint inhibitors for the PD1/PDL1 pathway: four anti-PD1 and three anti-PDL1 mAbs, including the anti-PD1 mAb dostarlimab, approved in April 2021. This report provides an updated landscape of PD1/PDL1 clinical trials, including use of approved therapies in the clinic and a summary of emerging modalities.

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD